ReviewCurrent opinion in drug discovery & development2010
The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
Review in Current opinion in drug discovery & development, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 69 citations in OpenAlex.
- Role of metabolites in drug-drug interactions.Drug metabolism and pharmacokinetics · 2026Review
- Biotransformation of ketamine in terminal in vivo experiments under chronic intermittent hypoxia conditions and the role of AhR.Archives of toxicology · 2025Article
- Metabolite Measurement in Index Substrate Drug Interaction Studies: A Review of the Literature and Recent New Drug Application Reviews.Metabolites · 2024Review
- Development of a human liver microphysiological coculture system for higher throughput chemical safety assessment.Toxicological sciences : an official journal of the Society of Toxicology · 2024Article
- White Rot Fungi as Tools for the Bioremediation of Xenobiotics: A Review.Journal of fungi (Basel, Switzerland) · 2024Review
- Anticancer Activity of Region B Capsaicin Analogs.Journal of medicinal chemistry · 2023Review
- In Silico Analyses of a Promising Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis Targeting Superoxide Dismutase I Protein.Pharmaceutics · 2023Article
- Review
- Cytochrome P450 Enzyme Inhibition and Herb-Drug Interaction Potential of Medicinal Plant Extracts Used for Management of Diabetes in Nigeria.European journal of drug metabolism and pharmacokinetics · 2021Article
- Contributions of UDP-Glucuronosyltransferases to Human Hepatic and Intestinal Metabolism of Ticagrelor and Inhibition of UGTs and Cytochrome P450 Enzymes by Ticagrelor and its Glucuronidated Metabolite.Frontiers in pharmacology · 2021Article
- Multienzyme Kinetics and Sequential Metabolism.Methods in molecular biology (Clifton, N.J.) · 2021Article
- The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats.BMC pharmacology & toxicology · 2020Article
- The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Quasi-Irreversible Inhibition of CYP2D6 by Berberine.Pharmaceutics · 2020Article
- Numerical Analysis of Time-Dependent Inhibition by MDMA.Drug metabolism and disposition: the biological fate of chemicals · 2020Article
- Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation.Clinical pharmacology and therapeutics · 2019Review
- Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Molecular pharmaceutics · 2018Article
- Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone.Molecules (Basel, Switzerland) · 2018Article
- A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?Current pharmacology reports · 2016Article
- Gemfibrozil in Combination with Statins-Is It Really Contraindicated?Current atherosclerosis reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The irreversible inhibition of cytochrome P450 (CYP) enzymes can cause significant drug-drug interactions (DDIs). The formation of metabolites is fundamental for the inactivation of CYP enzymes. Of the 19 CYP enzyme inactivators for which the mechanism of action has been established, 10 have circulating metabolites, which are on the metabolic pathway to inactivation of the CYP enzyme. Because inactivation of CYP enzymes usually requires multiple metabolic steps, the prediction of interactions between metabolites and CYPs in vivo may require complex models and the availability of data generated in vitro from each metabolite. Data discussed in this review suggest that circulating metabolites are more important in CYP inhibition in vivo than has been acknowledged.
Indexed as
Identifiers
20047147PMC2898504W241235916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.